Takeda Pharmaceutical Company Limited

Denso International America, Inc.

Fuji Photo Film Company, Limited

Takeda Pharmaceutical Company Limied

Minoru Sasaki

Keiko Kakegawa

Fumiaki Kikuchi

Zenichi Ikeda

Yoichi Nishikawa

Hiroki Sakamoto

Takanobu Kuroita

Hideyuki Igawa

Kouhei Asano

Takeshi Yamamoto

Hideyuki Sugiyama

Masahiro Ito

Takuto Kojima

Justin McBride

Kazuaki Takami

Tsuyoshi Maekawa

Tomohiro Okawa

Yasuyoshi Arikawa

Hironobu Maezaki

Yasutomi Asano

Ayumu Sato

Tohru Miyazaki

Jinichi Yonemori

Yasuhiro Imaeda

Toshihiro Wakamatsu

Yuta Tanaka

Misaki Homma

Akinori Toita

Hironori Kokubo

Osamu Kubo

Stephen Holcomb

Koji Fuji

Akira Sakashita

Masato Yoshikawa

Nobuo Furutachi

Minoru Nakamura

Tadahisa Sato

Takeshi Hirose

Masaki Seto

Masataka Murakami

Masaki Daini

Hideki Furukawa

Shigekazu Sasaki

Satoshi Mikami

Koichiro Fukuda

Yoshihiro Banno

Shinobu Sasaki

Masahiro Kamaura

Takatoshi Yogo

Tomohiro Ohashi

Kousuke Hidaka

Toshiki Murata

Takahito Kasahara

Nao Morishita

Kyoko Toyofuku

Florian Pünner

Takeshi Yasui

Shiinobu Sasaki

Hirotaka Kamitani

The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Heterocyclic compound

The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

HDAC6 inhibitory heterocyclic compound

A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. 

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (I) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification].

Fused heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification]. 

Condensed heterocyclic compound

A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein,or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

Provided is an aromatic ring compound having a glucagon antagonistic action, which is useful for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof has a superior glucagon antagonistic action, and is useful as a glucagon antagonist, a glucose production inhibitor or an agent for the prophylaxis or treatment of diabetes and the like.

Aromatic ring compound

Heterocyclic compounds, pharmaceutical agent and methods thereof, having superior pharmacological action and/or physicochemical properties, which are useful for the prophylaxis or treatment of circulatory diseases such as hypertension, cardiac diseases, arteriosclerosis, renal diseases and cerebral apoplexy and/or metabolic diseases such as hyperlipidemia, obesity and diabetes and/or central nervous disorders such as cerebral infarction, and/or mental diseases such as dementia depression and depression.

Heterocyclic compound and use thereof

A system for locating a vehicle may include a hand-held device and a communication device on-board the vehicle. The hand-held device may include a screen, and may be adapted to import a map and display a present location of the hand-held device on the map. The communication device on-board the vehicle may be adapted to communicate a present location of the vehicle to the hand-held device. The hand-held device may be capable of displaying the location of the vehicle and the location of the hand-held device on the map at the same time.

Car finder by cell phone

A compound represented by the formula (I): wherein R1 is an oxo group, &#x2550;N&#x2014;R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, &#x2014;CO&#x2014;R8 or &#x2014;O&#x2014;R8', or a salt thereof. For example, the compound may be substituted pyrimidines and pharmaceutical compositions of the formula (I) where X=&#x2014;CR3; X1=&#x2014;CR2 or &#x2014;NR2; and X2=&#x2014;CR5 or &#x2014;NR5. The compound of the present invention is useful as a drug for the prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases.

Substituted pyrimidines and [1,2, 4] triazoles and the use thereof for treating prophylaxis, cardiovascular diseases, metabolic diseases and/or central nervous system diseases

A compound represented by the formula (I):    

Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases

Growing community of inventors

Kanagawa, Japan

Minoru Sasaki